Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Bristol-Myers Squibb will emerge as a prominent player in the psychiatric disorder market in 2007. According to a new DR Pipelines Report from Decision Resources entitled Pipeline Analysis of Key Players in the Psychiatric Disorders Market, Bristol-Myers Squibb will experience a 5% increase in market share due to expected sales of Abilify for schizophrenia. Abilify should capture most new prescriptions and will continue to supplant older, typical agents in the United States.

The report also found that current market dominators Eli Lilly and GlaxoSmithKline (GSK) together owned approximately 43% of the psychiatric drug market in 2002.

"Lilly will remain the market leader in 2007 despite the loss of patent protection for Prozac, but GlaxoSmithKline will begin to loose its footing in the same year, said Karen O'Connor, analyst at Decision Resources. "The challenge to GlaxoSmithKline's growth is generic competition for Paxil, GSK's selective serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders."

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. The 2003 Pipeline series reveals which compounds are most clinically effective and commercially viable within five therapeutic markets: major metabolic diseases, psychiatric disorders, gastrointestinal diseases, respiratory diseases, and viral infections.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall for Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Nature Reviews Drug Discovery and Decision Resources Partner to Deliver Cutting-Edge Scientific Expertise With Market Analysis

View Now